Literature DB >> 19222885

A comparative study of prostate cancer detection and management in China and in France.

Eric Michaël Peyromaure1, Kaili Mao, Yinghao Sun, Shujie Xia, Nin Jiang, Shiqing Zhang, Gongxian Wang, Zhongmin Liu, Bernard Debré.   

Abstract

OBJECTIVE: To compare the detection and management of prostate cancer in one French and six Chinese urological institutions. PATIENTS AND METHODS: All the patients subjected to prostate biopsy for suspected prostate cancer in six Chinese urological institutions and in the department of urology of the Cochin hospital, France, between January 2003 and December 2005 were included. The characteristics of patients and tumors, and the management of prostate cancer were then analyzed.
RESULTS: In the Chinese institutions, 95.8% of patients undergoing prostate biopsy presented with urinary disorders. The rate of abnormal digital rectal examination (DRE) ranged from 29.2% to 45.1%. In the French institution, 72.7% of prostate biopsies were performed as a result of prostate cancer screening, and the rate of abnormal DRE was 16.8%. In the Chinese institutions, a total of 979 patients underwent prostate biopsy, with median PSA values varying between 10.2 ng/ml and 33 ng/ml among the institutions. Overall, 408 cases of prostate cancer were diagnosed, with median PSA values varying between 24.3 ng/dl and 174.9 ng/dl and 19.4% of tumors were clinically localized. In the French institution, 565 patients underwent prostate biopsy, with a median PSA value of 7.4 ng/ml and 251 cases of prostate cancer were diagnosed, with a median PSA value of 8.1 ng/ml and 80.9% of tumors were clinically localized. In the Chinese institutions, the majority of patients received surgical or medical castration. The rate of patients subjected to surgical castration varied between 24.2% and 100%. Radical prostatectomy (RP) was performed in only three Chinese hospitals, in which the percentage of patients treated with RP varied between 12.1% and 31.1%. In the French institution, RP was the most common treatment of prostate cancer (43.8% of patients).
CONCLUSION: In China, most patients subjected to prostate biopsy suffer from urinary symptoms and have elevated PSA levels. The lack of mass screening for prostate cancer results in a high rate of advanced tumors with nodal involvement and/or metastases. RP is rarely performed in Chinese hospitals, and castration represents the usual treatment of prostate cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19222885

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  19 in total

1.  Low expression of microRNA-30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein.

Authors:  Jun Zhang; Xilong Wang; Yangyun Wang; Ruixian Peng; Zhiyuan Lin; Yang Wang; Bo Hu; Jifeng Wang; Guowei Shi
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

2.  Diagnostic performance of microRNAs expression in prostate cancer.

Authors:  Qinfeng Yang; Yushan Zheng; Dequan Zhu
Journal:  Tumour Biol       Date:  2014-07-25

3.  A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer.

Authors:  Ping Tang; Hui Chen; Matthew Uhlman; Yu-Rong Lin; Xiang-Rong Deng; Bin Wang; Wen-Jun Yang; Ke-Ji Xie
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

4.  Laparoscopic radical prostatectomy plus extended lymph nodes dissection for cases with non-extra node metastatic prostate cancer: 5-year experience in a single Chinese institution.

Authors:  Ming-Kun Chen; Yun Luo; Hao Zhang; Jiang-Guang Qiu; Xin-Qiao Wen; Jun Pang; Jie Si-Tu; Qi-Peng Sun; Xin Gao
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-16       Impact factor: 4.553

5.  MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level.

Authors:  Dong Xue; Cui-Xing Zhou; Yun-Bo Shi; Hao Lu; Xiao-Zhou He
Journal:  Tumour Biol       Date:  2015-01-05

6.  Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma.

Authors:  Ziling Huang; Long Zhang; Xianghua Yi; Xiaoting Yu
Journal:  Tumour Biol       Date:  2015-10-24

7.  An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.

Authors:  Hai-Liang Zhang; Xiao-Jian Qin; Da-Long Cao; Yao Zhu; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2013-02-04       Impact factor: 3.285

Review 8.  Prostate cancer in Asian men.

Authors:  Kazuto Ito
Journal:  Nat Rev Urol       Date:  2014-03-04       Impact factor: 14.432

9.  The burden of prostate cancer in Asian nations.

Authors:  Jennifer Cullen; Sally Elsamanoudi; Stephen A Brassell; Yongmei Chen; Monica Colombo; Amita Srivastava; David G McLeod
Journal:  J Carcinog       Date:  2012-03-19

10.  Time point-independent tumor positivity of 68Ga-PSMA-PET/CT pre- and post-biopsy in high-risk prostate cancer.

Authors:  Sijuan Zou; Shuang Song; Jianyuan Zhou; Bo Yu; Dong Kuang; Zhihua Wang; Xiaohua Zhu
Journal:  Ann Nucl Med       Date:  2022-04-01       Impact factor: 2.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.